FDA Confirms Regulatory Review Period for Prandin Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Prandin, a human drug product, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce. This decision is in line with the law and aims to extend the patent protection for Prandin.